Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Vertex Pharmaceuticals Inc / Ma (VRTX) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Vertex Pharmaceuticals Inc / Ma. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 875320.
Total stock buying since 2014: $14,032,945.
Total stock sales since 2014: $1,196,910,074.
Total stock option exercises since 2014: $345,948,365.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 15,000 | $5,843,150 | 36,186 | $17,560,365 | 0 | $0 |
| 2024 | 0 | $0 | 148,610 | $67,869,390 | 14,306 | $1,623,040 |
| 2023 | 0 | $0 | 293,658 | $101,547,730 | 106,203 | $13,301,242 |
| 2022 | 0 | $0 | 299,056 | $84,212,962 | 129,539 | $14,304,907 |
| 2021 | 25,000 | $4,926,050 | 80,192 | $17,017,085 | 3,884 | $336,043 |
| 2020 | 15,000 | $3,263,745 | 823,381 | $212,996,253 | 593,830 | $68,989,498 |
| 2019 | 0 | $0 | 749,106 | $142,436,412 | 640,272 | $64,836,003 |
| 2018 | 0 | $0 | 677,893 | $111,360,024 | 569,594 | $48,688,330 |
| 2017 | 0 | $0 | 1,829,749 | $255,631,975 | 1,303,112 | $81,084,922 |
| 2016 | 0 | $0 | 425,204 | $38,606,160 | 329,295 | $11,861,367 |
| 2015 | 0 | $0 | 1,169,000 | $146,404,893 | 1,011,116 | $40,701,778 |
| 2014 | 0 | $0 | 10,500 | $1,266,825 | 10,500 | $221,235 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-12-30 | Young William D (Director) | Option Ex | 30,000 | 65.65 | 1,969,500 |
| 2019-12-09 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 5,000 | 225.00 | 1,125,000 |
| 2019-12-09 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 5,000 | 109.14 | 545,700 |
| 2019-11-25 | Kewalramani Reshma (EVP and CMO) | Sale | 4,692 | 219.37 | 1,029,284 |
| 2019-11-25 | Kewalramani Reshma (EVP and CMO) | Option Ex | 4,692 | 187.53 | 879,890 |
| 2019-11-25 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,910 | 219.37 | 857,736 |
| 2019-11-25 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 3,910 | 187.53 | 733,242 |
| 2019-11-25 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 5,000 | 220.00 | 1,100,000 |
| 2019-11-25 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 5,000 | 109.14 | 545,700 |
| 2019-11-19 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 5,000 | 215.00 | 1,075,000 |
| 2019-11-19 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 5,000 | 109.14 | 545,700 |
| 2019-11-19 | Leiden Jeffrey M (CEO & President) | Sale | 96,534 | 211.53 | 20,419,837 |
| 2019-11-19 | Leiden Jeffrey M (CEO & President) | Option Ex | 96,534 | 120.52 | 11,633,795 |
| 2019-11-18 | Leiden Jeffrey M (CEO & President) | Sale | 4,434 | 210.00 | 931,140 |
| 2019-11-18 | Leiden Jeffrey M (CEO & President) | Option Ex | 4,434 | 120.52 | 534,363 |
| 2019-11-15 | Tatsis Ourania (SVP, CRO) | Sale | 5 | 205.95 | 1,029 |
| 2019-11-15 | Kewalramani Reshma (EVP and CMO) | Sale | 61 | 205.95 | 12,562 |
| 2019-11-15 | Parini Michael (EVP, CL&AO) | Sale | 84 | 205.95 | 17,299 |
| 2019-11-15 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 19 | 205.95 | 3,913 |
| 2019-11-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 60 | 205.95 | 12,357 |
| 2019-11-15 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 57 | 205.95 | 11,739 |
| 2019-11-15 | Leiden Jeffrey M (CEO & President) | Sale | 5,000 | 210.00 | 1,050,000 |
| 2019-11-15 | Leiden Jeffrey M (CEO & President) | Option Ex | 5,000 | 120.52 | 602,575 |
| 2019-11-13 | Tatsis Ourania (SVP, CRO) | Sale | 2,853 | 205.59 | 586,548 |
| 2019-11-13 | Tatsis Ourania (SVP, CRO) | Option Ex | 2,853 | 155.57 | 443,841 |
| 2019-11-13 | Parini Michael (EVP, CL&AO) | Sale | 4,892 | 205.50 | 1,005,306 |
| 2019-11-13 | Parini Michael (EVP, CL&AO) | Option Ex | 4,892 | 155.57 | 761,048 |
| 2019-11-13 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 8,560 | 205.57 | 1,759,679 |
| 2019-11-13 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 8,560 | 155.57 | 1,331,679 |
| 2019-11-08 | Kewalramani Reshma (EVP and CMO) | Sale | 509 | 199.00 | 101,291 |
| 2019-11-08 | Kewalramani Reshma (EVP and CMO) | Option Ex | 509 | 155.57 | 79,185 |
| 2019-11-06 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,223 | 197.12 | 241,077 |
| 2019-11-06 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,223 | 155.57 | 190,262 |
| 2019-11-04 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 3,708 | 201.62 | 747,606 |
| 2019-11-04 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 3,708 | 88.78 | 329,214 |
| 2019-11-04 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,126 | 200.75 | 828,273 |
| 2019-11-04 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 4,126 | 88.78 | 366,326 |
| 2019-11-04 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 4,097 | 200.33 | 820,752 |
| 2019-11-04 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 4,097 | 88.78 | 363,752 |
| 2019-11-01 | Bhatia Sangeeta N. (Director) | Sale | 1,291 | 200.00 | 258,200 |
| 2019-11-01 | Bhatia Sangeeta N. (Director) | Option Ex | 1,291 | 152.74 | 197,187 |
| 2019-10-30 | Kewalramani Reshma (EVP and CMO) | Sale | 3,057 | 199.00 | 608,343 |
| 2019-10-30 | Kewalramani Reshma (EVP and CMO) | Option Ex | 3,057 | 155.57 | 475,577 |
| 2019-10-25 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 4,311 | 195.01 | 840,688 |
| 2019-10-25 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 4,311 | 91.05 | 392,516 |
| 2019-10-22 | Kewalramani Reshma (EVP and CMO) | Sale | 638 | 189.00 | 120,582 |
| 2019-10-22 | Altshuler David (EVP, Global Research and CSO) | Sale | 3,669 | 194.37 | 713,143 |
| 2019-10-22 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 3,669 | 155.57 | 570,786 |
| 2019-10-22 | Sachdev Amit (EVP, Chief Patient Officer) | Sale | 3,883 | 190.27 | 738,818 |
| 2019-10-22 | Sachdev Amit (EVP, Chief Patient Officer) | Option Ex | 3,883 | 86.52 | 335,957 |
| 2019-10-22 | Leiden Jeffrey M (CEO & President) | Sale | 107,831 | 190.00 | 20,487,890 |
| 2019-10-22 | Leiden Jeffrey M (CEO & President) | Option Ex | 107,831 | 120.52 | 12,995,252 |
| 2019-10-22 | Mcglynn Margaret G (Director) | Sale | 20,000 | 190.00 | 3,800,000 |
| 2019-10-22 | Mcglynn Margaret G (Director) | Option Ex | 20,000 | 72.14 | 1,442,800 |
| 2019-10-17 | Parini Michael (EVP, CL&AO) | Sale | 4,250 | 177.80 | 755,650 |
| 2019-10-17 | Parini Michael (EVP, CL&AO) | Option Ex | 4,250 | 122.45 | 520,412 |
| 2019-10-14 | Parini Michael (EVP, CL&AO) | Sale | 2,125 | 174.33 | 370,457 |
| 2019-10-14 | Parini Michael (EVP, CL&AO) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2019-10-02 | Tatsis Ourania (SVP, CRO) | Sale | 444 | 167.69 | 74,454 |
| 2019-10-02 | Bhatia Sangeeta N. (Director) | Sale | 8,379 | 166.93 | 1,398,681 |
| 2019-10-02 | Bhatia Sangeeta N. (Director) | Option Ex | 7,088 | 126.19 | 894,470 |
| 2019-10-01 | Tatsis Ourania (SVP, CRO) | Sale | 188 | 169.11 | 31,792 |
| 2019-08-19 | Altshuler David (EVP, Global Research and CSO) | Sale | 12,501 | 186.39 | 2,330,011 |
| 2019-08-19 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 12,501 | 103.15 | 1,289,515 |
| 2019-08-13 | Mcglynn Margaret G (Director) | Sale | 10,000 | 185.00 | 1,850,000 |
| 2019-08-13 | Mcglynn Margaret G (Director) | Option Ex | 10,000 | 81.54 | 815,400 |
| 2019-08-08 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,125 | 181.89 | 386,516 |
| 2019-08-08 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2019-08-05 | Parini Michael (EVP, CL&AO) | Sale | 2,330 | 175.12 | 408,041 |
| 2019-08-05 | Parini Michael (EVP, CL&AO) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2019-08-05 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 1,553 | 176.44 | 274,011 |
| 2019-08-05 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 1,553 | 86.52 | 134,365 |
| 2019-08-02 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,155 | 177.78 | 383,115 |
| 2019-08-02 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,155 | 91.05 | 196,212 |
| 2019-07-12 | Parini Michael (EVP, CL&AO) | Sale | 2,125 | 175.41 | 372,746 |
| 2019-07-12 | Parini Michael (EVP, CL&AO) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2019-07-05 | Parini Michael (EVP, CL&AO) | Sale | 4,250 | 180.11 | 765,467 |
| 2019-07-05 | Parini Michael (EVP, CL&AO) | Option Ex | 4,250 | 122.45 | 520,412 |
| 2019-06-19 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,125 | 181.89 | 386,516 |
| 2019-06-19 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2019-06-18 | Leiden Jeffrey M (CEO & President) | Sale | 56,030 | 175.72 | 9,845,591 |
| 2019-06-18 | Leiden Jeffrey M (CEO & President) | Option Ex | 56,030 | 77.31 | 4,331,679 |
| 2019-06-03 | Bhatia Sangeeta N. (Director) | Sale | 720 | 167.15 | 120,348 |
| 2019-05-30 | Parini Michael (EVP, CL&AO) | Sale | 707 | 173.00 | 122,311 |
| 2019-05-24 | Leiden Jeffrey M (CEO & President) | Sale | 113,432 | 175.10 | 19,861,943 |
| 2019-05-24 | Leiden Jeffrey M (CEO & President) | Option Ex | 113,432 | 77.31 | 8,769,427 |
| 2019-05-15 | Kewalramani Reshma (EVP and CMO) | Sale | 241 | 165.41 | 39,863 |
| 2019-05-15 | Parini Michael (EVP, CL&AO) | Sale | 83 | 165.41 | 13,729 |
| 2019-05-15 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 133 | 165.41 | 21,999 |
| 2019-05-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 91 | 165.41 | 15,052 |
| 2019-05-15 | Silva Paul M (SVP & Controller) | Sale | 161 | 165.41 | 26,631 |
| 2019-05-15 | Sachdev Amit (EVP, CRO) | Sale | 61 | 165.41 | 10,090 |
| 2019-05-06 | Leiden Jeffrey M (CEO & President) | Sale | 33,058 | 175.01 | 5,785,645 |
| 2019-05-06 | Leiden Jeffrey M (CEO & President) | Option Ex | 33,058 | 77.31 | 2,555,713 |
| 2019-05-03 | Parini Michael (EVP, CL&AO) | Sale | 1,622 | 171.92 | 278,854 |
| 2019-05-03 | Parini Michael (EVP, CL&AO) | Option Ex | 2,329 | 86.52 | 201,505 |
| 2019-05-03 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 1,553 | 171.98 | 267,084 |
| 2019-05-03 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 1,553 | 86.52 | 134,365 |
| 2019-05-02 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,155 | 170.07 | 366,507 |
| 2019-05-02 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,155 | 91.05 | 196,212 |
| 2019-04-16 | Parini Michael (EVP, CL&AO) | Sale | 6,375 | 182.22 | 1,161,684 |
| 2019-04-16 | Parini Michael (EVP, CL&AO) | Option Ex | 6,375 | 106.37 | 678,108 |
| 2019-04-15 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 5,624 | 182.28 | 1,025,159 |
| 2019-02-19 | Kewalramani Reshma (EVP and CMO) | Sale | 1,488 | 187.50 | 279,004 |
| 2019-02-19 | Parini Michael (EVP, CL&AO) | Sale | 5,624 | 187.58 | 1,054,966 |
| 2019-02-19 | Altshuler David (EVP, Global Research and CSO) | Sale | 5,624 | 187.60 | 1,055,062 |
| 2019-02-19 | Silva Paul M (SVP & Interim CFO) | Sale | 2,812 | 187.51 | 527,269 |
| 2019-02-19 | Leiden Jeffrey M (CEO & President) | Sale | 20,997 | 187.61 | 3,939,310 |
| 2019-02-11 | Silva Paul M (SVP & Interim CFO) | Sale | 4,215 | 180.27 | 759,850 |
| 2019-02-06 | Silva Paul M (SVP & Interim CFO) | Sale | 1,289 | 193.00 | 248,777 |
| 2019-02-06 | Silva Paul M (SVP & Interim CFO) | Option Ex | 1,289 | 91.05 | 117,363 |
| 2019-02-04 | Parini Michael (EVP, CL&AO) | Sale | 2,330 | 189.19 | 440,812 |
| 2019-02-04 | Parini Michael (EVP, CL&AO) | Option Ex | 2,330 | 86.52 | 201,591 |
| 2019-02-04 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 18,309 | 186.46 | 3,413,804 |
| 2019-02-04 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 7,959 | 95.66 | 761,357 |
| 2019-02-04 | Altshuler David (EVP, Global Research and CSO) | Sale | 4,126 | 189.19 | 780,597 |
| 2019-02-04 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 4,126 | 88.78 | 366,326 |
| 2019-02-04 | Silva Paul M (SVP & Interim CFO) | Sale | 4,247 | 187.13 | 794,741 |
| 2019-02-04 | Silva Paul M (SVP & Interim CFO) | Option Ex | 809 | 86.52 | 69,994 |
| 2019-02-04 | Sachdev Amit (EVP, CRO) | Sale | 12,722 | 186.92 | 2,377,996 |
| 2019-02-04 | Sachdev Amit (EVP, CRO) | Option Ex | 4,097 | 88.78 | 363,752 |
| 2019-02-04 | Leiden Jeffrey M (CEO & President) | Sale | 32,250 | 186.43 | 6,012,206 |
| 2019-02-01 | Parini Michael (EVP, CL&AO) | Sale | 3,450 | 190.92 | 658,674 |
| 2019-01-22 | Parini Michael (EVP, CL&AO) | Sale | 3,668 | 195.00 | 715,260 |
| 2019-01-22 | Parini Michael (EVP, CL&AO) | Option Ex | 3,668 | 155.57 | 570,630 |
| 2019-01-22 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,125 | 193.48 | 411,145 |
| 2019-01-22 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2019-01-22 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,125 | 193.48 | 411,145 |
| 2019-01-22 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2019-01-18 | Altshuler David (EVP, Global Research and CSO) | Sale | 1,223 | 194.62 | 238,020 |
| 2019-01-18 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 1,223 | 155.70 | 190,421 |
| 2019-01-17 | Silva Paul M (SVP & Corp Controller) | Sale | 3,007 | 190.54 | 572,962 |
| 2019-01-17 | Silva Paul M (SVP & Corp Controller) | Option Ex | 3,007 | 90.54 | 272,262 |
| 2019-01-14 | Parini Michael (EVP, CL&AO) | Sale | 2,125 | 186.71 | 396,758 |
| 2019-01-14 | Parini Michael (EVP, CL&AO) | Option Ex | 2,125 | 90.29 | 191,866 |
| 2019-01-04 | Parini Michael (EVP, CL&AO) | Sale | 4,250 | 165.90 | 705,075 |
| 2019-01-04 | Parini Michael (EVP, CL&AO) | Option Ex | 4,250 | 122.45 | 520,412 |
| 2018-12-06 | Sachs Bruce I (Director) | Option Ex | 10,000 | 34.24 | 342,400 |
| 2018-12-03 | Silva Paul M (SVP & Corp Controller) | Sale | 809 | 186.52 | 150,894 |
| 2018-12-03 | Silva Paul M (SVP & Corp Controller) | Option Ex | 809 | 86.52 | 69,994 |
| 2018-11-15 | Parini Michael (EVP, CL&AO) | Sale | 90 | 163.75 | 14,737 |
| 2018-11-15 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 29 | 163.75 | 4,748 |
| 2018-11-15 | Altshuler David (EVP, Global Research and CSO) | Sale | 100 | 163.75 | 16,375 |
| 2018-11-15 | Silva Paul M (SVP & Corp Controller) | Sale | 12 | 163.75 | 1,965 |
| 2018-11-07 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Sale | 2,125 | 179.00 | 380,375 |
| 2018-11-07 | Arbuckle Stuart A (EVP\Chief Commercial Officer) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2018-11-07 | Altshuler David (EVP, Global Research and CSO) | Sale | 2,125 | 181.89 | 386,516 |
| 2018-11-07 | Altshuler David (EVP, Global Research and CSO) | Option Ex | 2,125 | 131.89 | 280,266 |
| 2018-11-05 | Parini Michael (EVP, CL&AO) | Sale | 2,330 | 172.08 | 400,946 |
| 2018-11-05 | Parini Michael (EVP, CL&AO) | Option Ex | 2,330 | 86.52 | 201,591 |
Insider trading activities including stock purchases, stock sales, and option exercises of VRTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Vertex Pharmaceuticals Inc / Ma (symbol VRTX, CIK number 875320) see the Securities and Exchange Commission (SEC) website.